Credit: Getty Images. No new safety signals were observed in this patient population. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ruxolitinib ...
Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...
Arcutis Biotherapeutics is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than a quarter of patients achieved a clear or ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AD affected more than 35% body surface area of study ...
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) ...
A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...
Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings, roflumilast ...
How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...
The eutectic mixture EMLA cream has many medical uses, including pain relief for hemodialyzed patients prior to cannulation. Cutaneous side effects associated with its application have rarely been ...
Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results